P2.01-82 Neutrophil-To-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1136
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors

Scientific Reports
Multidisciplinary
2019English

PD‑L1 Expression Is Associated With Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2016English

Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
2019English

Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature

Cancer
Cancer ResearchOncology
2017English

P3.04-13 PD-L1-Gene Expression by nCounter Correlates With PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak
2018English

P1.16-03 Prognostic Significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immunotherapies Based on PD-1/PD-L1 Pathway Inhibitors in Ovarian Cancer Treatment

Clinical and Experimental Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy